Alnylam board changes: Bonney and Bertozzi resign; Arbuckle appointed director

ALNYLAM PHARMACEUTICALS, INC.

Mike Bonney and Carolyn Bertozzi resigned from Alnylam board effective Dec 2, 2025; no disagreement with company.
Bertozzi resigned due to election to Eli Lilly board (eff. Dec 8, 2025); will continue as scientific advisor.
Stuart Arbuckle (ex-Vertex COO) elected to board, effective Jan 5, 2026; receives $75K annual cash retainer plus stock.
Board size reduced from 11 to 10 following resignations; Arbuckle serves as Class I director until 2026 annual meeting.
Arbuckle brings commercial and leadership experience from GSK, Amgen, and Vertex; also serves on Rhythm Pharma board.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.